Charles River Laboratories International 

€169.75
63
-€0.1-0.06% Aujourd'hui

Statistiques

Jour Haut
169.75
Journée basse
169.75
52W Haut
-
52W Bas
-
Volume
0
Volume moyen
-
Cap boursière
10.21B
Ratio C/B
23.65
Rendement de dividendes
-
Dividende
-

À venir

Bénéfices

30OctPrévu
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Suivant
2.06
2.31
2.55
2.8
BPA prévu
2.421052
BPA réel
S. O.

Sont également suivis

Cette liste est basée sur les listes de surveillance des personnes sur Stock Events qui suivent RV6.F. Il ne s'agit pas d'une recommandation d'investissement.

Concurrents

Cette liste est une analyse basée sur les événements récents du marché. Ce n'est pas une recommandation d'investissement.

Cote des analystes

219.88Cours Moyen Cible
L'estimation la plus élevée est €250.
Sur la base de 9 notations au cours des 6 derniers mois. Il ne s'agit pas d'une recommandation d'investissement.
Acheter
33%
Détenir
67%
Vendre
0%

À propos de nous

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Show more...
PDG
Mr. James C. Foster J.D.
Employés
20400
Pays
US
ISIN
US1598641074
WKN
000939391

Cotation